JP2021533199A5 - - Google Patents
Info
- Publication number
- JP2021533199A5 JP2021533199A5 JP2021529260A JP2021529260A JP2021533199A5 JP 2021533199 A5 JP2021533199 A5 JP 2021533199A5 JP 2021529260 A JP2021529260 A JP 2021529260A JP 2021529260 A JP2021529260 A JP 2021529260A JP 2021533199 A5 JP2021533199 A5 JP 2021533199A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- complex according
- transferrin receptor
- nucleotides
- dmpk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025004577A JP7847681B2 (ja) | 2018-08-02 | 2025-01-14 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713914P | 2018-08-02 | 2018-08-02 | |
| US62/713,914 | 2018-08-02 | ||
| US201862779161P | 2018-12-13 | 2018-12-13 | |
| US62/779,161 | 2018-12-13 | ||
| US201962855761P | 2019-05-31 | 2019-05-31 | |
| US62/855,761 | 2019-05-31 | ||
| US201962858888P | 2019-06-07 | 2019-06-07 | |
| US62/858,888 | 2019-06-07 | ||
| US201962859672P | 2019-06-10 | 2019-06-10 | |
| US62/859,672 | 2019-06-10 | ||
| PCT/US2019/044987 WO2020028861A1 (en) | 2018-08-02 | 2019-08-02 | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025004577A Division JP7847681B2 (ja) | 2018-08-02 | 2025-01-14 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533199A JP2021533199A (ja) | 2021-12-02 |
| JP2021533199A5 true JP2021533199A5 (enExample) | 2022-08-09 |
| JP7705793B2 JP7705793B2 (ja) | 2025-07-10 |
Family
ID=69230803
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529260A Active JP7705793B2 (ja) | 2018-08-02 | 2019-08-02 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| JP2025004577A Active JP7847681B2 (ja) | 2018-08-02 | 2025-01-14 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025004577A Active JP7847681B2 (ja) | 2018-08-02 | 2025-01-14 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210308272A1 (enExample) |
| EP (1) | EP3829596A4 (enExample) |
| JP (2) | JP7705793B2 (enExample) |
| KR (1) | KR20210081323A (enExample) |
| CN (1) | CN112955154A (enExample) |
| AU (2) | AU2019314538B2 (enExample) |
| CA (1) | CA3108287A1 (enExample) |
| IL (2) | IL321905A (enExample) |
| MX (1) | MX2021001283A (enExample) |
| SG (1) | SG11202100925VA (enExample) |
| WO (1) | WO2020028861A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118638788A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP7611825B2 (ja) | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| WO2021142217A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Thereapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of milck1 |
| US12624120B2 (en) | 2020-01-31 | 2026-05-12 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TfR) antibody and uses thereof |
| WO2021195469A1 (en) * | 2020-03-27 | 2021-09-30 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
| CN116348139A (zh) * | 2020-07-23 | 2023-06-27 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途 |
| IL299663A (en) * | 2020-07-23 | 2023-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and their uses for the treatment of myotonic dystrophy |
| AU2021342155A1 (en) * | 2020-09-11 | 2023-04-13 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use |
| US20240100177A1 (en) * | 2020-12-04 | 2024-03-28 | Dyne Therapeutics, Inc. | Antibody-oligonucleotide complexes and uses thereof |
| CA3202832A1 (en) * | 2020-12-31 | 2022-07-07 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| CN117980006A (zh) | 2021-07-09 | 2024-05-03 | 达因疗法公司 | 用于治疗肌养蛋白病的肌肉靶向复合物和制剂 |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US20240358846A1 (en) * | 2021-07-30 | 2024-10-31 | 4Basebio, S.L.U. | Nanoparticles and Peptides for the Delivery of Cargos to Muscle Cells |
| EP4124345A1 (en) * | 2021-07-30 | 2023-02-01 | 4basebio UK Ltd | Nanoparticles for muscle delivery |
| MX2024002753A (es) | 2021-09-01 | 2024-05-20 | Biogen Ma Inc | Anticuerpos anti receptor de transferrina y usos de los mismos. |
| US11833221B2 (en) | 2021-09-01 | 2023-12-05 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds for reducing DMPK expression |
| KR20250004770A (ko) | 2022-04-15 | 2025-01-08 | 다인 세라퓨틱스, 인크. | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제 |
| WO2025160275A1 (en) | 2024-01-24 | 2025-07-31 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009005793A2 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| EP3489360A3 (en) | 2010-07-19 | 2019-08-28 | Ionis Pharmaceuticals, Inc. | Modulation of nuclear-retained rna |
| WO2013138662A1 (en) | 2012-03-16 | 2013-09-19 | 4S3 Bioscience, Inc. | Antisense conjugates for decreasing expression of dmpk |
| KR102240217B1 (ko) | 2012-09-25 | 2021-04-14 | 젠자임 코포레이션 | 근긴장성 이영양증의 치료용 펩티드-결합 모르폴리노 안티센스 올리고뉴클레오티드 |
| ES2659270T5 (en) * | 2012-10-23 | 2026-02-11 | Synaffix Bv | Modified antibody, antibody-conjugate and process for the preparation thereof |
| TW201536329A (zh) * | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
| US20190240346A1 (en) | 2016-06-20 | 2019-08-08 | Genahead Bio, Inc. | Antibody-drug conjugate |
| CN110381980A (zh) | 2017-01-06 | 2019-10-25 | 艾维迪提生物科学有限责任公司 | 核酸-多肽组合物以及诱导外显子跳读的方法 |
-
2019
- 2019-08-02 CA CA3108287A patent/CA3108287A1/en active Pending
- 2019-08-02 IL IL321905A patent/IL321905A/en unknown
- 2019-08-02 SG SG11202100925VA patent/SG11202100925VA/en unknown
- 2019-08-02 EP EP19843799.8A patent/EP3829596A4/en active Pending
- 2019-08-02 CN CN201980062906.7A patent/CN112955154A/zh active Pending
- 2019-08-02 KR KR1020217005992A patent/KR20210081323A/ko active Pending
- 2019-08-02 JP JP2021529260A patent/JP7705793B2/ja active Active
- 2019-08-02 IL IL280425A patent/IL280425B2/en unknown
- 2019-08-02 WO PCT/US2019/044987 patent/WO2020028861A1/en not_active Ceased
- 2019-08-02 US US17/264,905 patent/US20210308272A1/en not_active Abandoned
- 2019-08-02 MX MX2021001283A patent/MX2021001283A/es unknown
- 2019-08-02 AU AU2019314538A patent/AU2019314538B2/en active Active
-
2025
- 2025-01-14 JP JP2025004577A patent/JP7847681B2/ja active Active
- 2025-05-30 AU AU2025204039A patent/AU2025204039A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533200A5 (enExample) | ||
| JP2021533197A5 (enExample) | ||
| JP2025067909A5 (enExample) | ||
| JP2021532832A5 (enExample) | ||
| JP2021533198A5 (enExample) | ||
| JP2023509793A5 (enExample) | ||
| JP2023512442A5 (enExample) | ||
| JP2023512441A5 (enExample) | ||
| JP2023510351A5 (enExample) | ||
| JP2023535078A5 (enExample) | ||
| JP2023535444A5 (enExample) | ||
| JP2023535073A5 (enExample) | ||
| JP2024525614A5 (enExample) | ||
| JP2022122928A5 (enExample) | ||
| JP2023179497A (ja) | Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法 | |
| JP2020505330A5 (enExample) | ||
| JP2021532831A5 (enExample) | ||
| JP2022513482A5 (enExample) | ||
| JP2023537798A5 (enExample) | ||
| JP2024527362A5 (enExample) | ||
| JP2024524222A5 (enExample) | ||
| JP2023527638A5 (enExample) | ||
| JP2024546436A5 (enExample) | ||
| IL317871A (en) | Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy | |
| CN112955154A (zh) | 肌肉靶向复合物及其用于治疗强直性肌营养不良的用途 |